These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 21112407

  • 1. Rapid detection of ABC transporter interaction: potential utility in pharmacology.
    Robey RW, Lin B, Qiu J, Chan LL, Bates SE.
    J Pharmacol Toxicol Methods; 2011; 63(3):217-22. PubMed ID: 21112407
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS.
    Daood M, Tsai C, Ahdab-Barmada M, Watchko JF.
    Neuropediatrics; 2008 Aug; 39(4):211-8. PubMed ID: 19165709
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein.
    Fujita Y, Noguchi K, Suzuki T, Katayama K, Sugimoto Y.
    BMC Res Notes; 2013 Nov 06; 6():445. PubMed ID: 24196382
    [Abstract] [Full Text] [Related]

  • 8. The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).
    Kannan P, Telu S, Shukla S, Ambudkar SV, Pike VW, Halldin C, Gottesman MM, Innis RB, Hall MD.
    ACS Chem Neurosci; 2011 Feb 16; 2(2):82-9. PubMed ID: 22778859
    [Abstract] [Full Text] [Related]

  • 9. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
    Shukla S, Robey RW, Bates SE, Ambudkar SV.
    Drug Metab Dispos; 2009 Feb 16; 37(2):359-65. PubMed ID: 18971320
    [Abstract] [Full Text] [Related]

  • 10. Assessment of drug transporter function using fluorescent cell imaging.
    Bircsak KM, Gibson CJ, Robey RW, Aleksunes LM.
    Curr Protoc Toxicol; 2013 Sep 23; 57():Unit 23.6.. PubMed ID: 24510579
    [Abstract] [Full Text] [Related]

  • 11. Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells.
    Hirayama C, Watanabe H, Nakashima R, Nanbu T, Hamada A, Kuniyasu A, Nakayama H, Kawaguchi T, Saito H.
    Pharm Res; 2008 Apr 23; 25(4):827-35. PubMed ID: 17934801
    [Abstract] [Full Text] [Related]

  • 12. Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance.
    Kwatra D, Vadlapatla RK, Vadlapudi AD, Pal D, Mitra AK.
    Int J Pharm; 2010 Aug 16; 395(1-2):114-21. PubMed ID: 20573570
    [Abstract] [Full Text] [Related]

  • 13. Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2.
    Eadie LN, Saunders VA, Hughes TP, White DL.
    Leuk Lymphoma; 2013 Mar 16; 54(3):569-78. PubMed ID: 22845311
    [Abstract] [Full Text] [Related]

  • 14. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.
    Natarajan K, Bhullar J, Shukla S, Burcu M, Chen ZS, Ambudkar SV, Baer MR.
    Biochem Pharmacol; 2013 Feb 15; 85(4):514-24. PubMed ID: 23261525
    [Abstract] [Full Text] [Related]

  • 15. Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp.
    Zhang Y, Laterra J, Pomper MG.
    Neoplasia; 2009 Jan 15; 11(1):96-101. PubMed ID: 19107236
    [Abstract] [Full Text] [Related]

  • 16. Tetrahydrocannabinol and Its Major Metabolites Are Not (or Are Poor) Substrates or Inhibitors of Human P-Glycoprotein [ATP-Binding Cassette (ABC) B1] and Breast Cancer Resistance Protein (ABCG2).
    Chen X, Unadkat JD, Mao Q.
    Drug Metab Dispos; 2021 Oct 15; 49(10):910-918. PubMed ID: 34326138
    [Abstract] [Full Text] [Related]

  • 17. The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions.
    Bhullar J, Natarajan K, Shukla S, Mathias TJ, Sadowska M, Ambudkar SV, Baer MR.
    PLoS One; 2013 Oct 15; 8(8):e71266. PubMed ID: 23967177
    [Abstract] [Full Text] [Related]

  • 18. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters.
    Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR, Chen X, Chen ZS.
    Biochem Pharmacol; 2009 Jul 15; 78(2):153-61. PubMed ID: 19427995
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).
    Robey RW, Shukla S, Finley EM, Oldham RK, Barnett D, Ambudkar SV, Fojo T, Bates SE.
    Biochem Pharmacol; 2008 Mar 15; 75(6):1302-12. PubMed ID: 18234154
    [Abstract] [Full Text] [Related]

  • 20. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.
    Sen R, Natarajan K, Bhullar J, Shukla S, Fang HB, Cai L, Chen ZS, Ambudkar SV, Baer MR.
    Mol Cancer Ther; 2012 Sep 15; 11(9):2033-44. PubMed ID: 22778153
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.